Press Releases

When virologists become reality TV stars, biologists dream of life without illness, researchers debate organoids vs. animal testing with the general public, and biomedical scientists discuss the possibilities of AI, it can only be Berlin Science Week. This year, the MDC is holding a number of virtual events.

The Berlin biotech start-up T-knife, a spin-off from the MDC together with Charité, has secured investments totaling €66 million. Four venture capital funds committed to the financing in early August. T-knife develops new cancer treatments using modified immune system T cells.

Researchers from the MDC have developed a new tool that makes it easier to maximize the power of deep learning for studying genomics. They describe the new approach, Janggu, in the journal Nature Communications.

In light of the pandemic, the Max Delbrück Center for Molecular Medicine (MDC) is pooling together its resources for projects that advance the understanding of SARS-CoV-2, while scaling down its regular research operations to a minimum. Here’s an overview of the MDC’s current collaborations and plans.

Single cell technologies for Personalized Medicine – The Berlin Institute of Health (BIH), the Berlin Institute for Medical Systems Biology (BIMSB) of the Max Delbrück Center for Molecular Medicine (MDC) and Charité – Universitätsmedizin Berlin are launching a joint research initiative.

An artificial intelligence platform developed at the Max Delbrück Center for Molecular Medicine (MDC) can analyze genomic data extremely quickly, picking out key patterns to classify different types of colorectal tumors and improve the drug discovery process. The deeper analysis shows some colorectal subtypes need to be reclassified.

More than 450 scientists, clinicians, patients, and stakeholders from 20 European countries have gathered in Berlin at the LifeTime Opening Conference. The pan-European initiative aims to revolutionize healthcare.

The Opening Conference of LifeTime will take place on 6 and 7 May 2019 in Berlin. The pan-European research initiative aims to develop new technologies for the treatment and early detection of diseases.

An MDC research team has discovered surprising new properties in fluconazole, a long approved fungal drug. The substance helps to draw water from urine. The researchers found this in rodents. The fungicide could help patients with rare genetic diseases in whom the water transport of the kidneys is impaired. Nevertheless, the path to therapy is not easy.

LifeTime is one of the six winners of an EU-wide competition in which ambitious and forward-looking research projects are selected and funded. This was officially announced by the European Commission on Tuesday. The coordinators of LifeTime in Berlin and Paris were pleased that they can now begin the actual work. Chancellor Merkel praised the initiative.